A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
OBJECTIVES: To explore the association of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on heart rate (HR) in overweight or obese patients without diabetes. METHODS: A comprehensive search of the PubMed, Web of Science, Embase, and Cochrane Li…
BACKGROUND: Alzheimer's disease (AD) and Diabetes Mellitus Type II (DM2) share overlapping biological mechanisms, and diabetes increases the risk of developing AD. Treatments that modify the course of diabetes, such as metformin and semaglutide, have…
Complement inhibitors are expanding their indications in nephrology. In patients with type 2 diabetes, semaglutide prevents chronic kidney disease (CKD), while retatrutide reduces albuminuria in patients with diabetes and established CKD. Obinutuzuma…
Metabolic disorders have been recognized as a major contributor to the occurrence and progression of osteoarthritis (OA). Identifying novel therapeutic agents to ameliorate the progression of OA with metabolic disorder is crucial. In this study, we d…
INTRODUCTION: Pharmacological therapies are recommended for individuals with obesity. Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1), and tirzepatide, a dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist (GI…
BACKGROUND: Obesity is a chronic metabolic disease associated with substantial cardiometabolic risk and long-term morbidity. Although randomized controlled trials have demonstrated the efficacy of incretin-based therapies, real-world comparative data…
BACKGROUND: Peripheral artery disease (PAD) is a prevalent and debilitating complication of diabetes and obesity, yet it remains underrecognized and undertreated. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, have shown…
OBJECTIVES: To evaluate the impact of semaglutide on body mass index (BMI) and cardiometabolic markers in adolescents with obesity and genetic variants associated with monogenic or syndromic obesity. METHODS: A retrospective chart review was conducte…
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, is increasingly used for the treatment of diabetes and weight loss, including in women of reproductive age. However, its impact on pregnancy outcomes remains largely unknown, with l…
BACKGROUND: Novel treatments are needed for the primary and secondary prevention of heart failure in patients with type 2 diabetes, including individuals with and those without a history of heart failure. Conflicting trial evidence exists on whether…
INTRODUCTION: Type 2 diabetes mellitus (T2DM) significantly impacts the patients' quality of life due to chronic complications and associated comorbidities. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated benefits in glycemic…
In late 2025, the White House announced new Most Favored Nation (MFN) pricing agreements for the glucagon-like peptide-1 receptor agonist class, including 3 semaglutide products, establishing substantially lower prices for Medicare and Medicaid. Shor…
We present the case of a 60-year-old woman with metastatic breast cancer who underwent 18 F-FDG PET/CT for treatment response assessment. Beyond oncologic findings, the scan revealed abnormal gastric retention, gallbladder, colonic, and renal uptake…
Heart failure (HF) is associated with high morbidity and mortality. HF with preserved left ventricular ejection fraction (HF-pEF) accounts for up to 50% of all HF cases, being the most common in elderly patients. In addition, these subjects frequentl…
BACKGROUND: Anterior lumbar interbody fusion (ALIF) is frequently performed to treat degenerative spine disease. Outcomes, however, may be affected by obesity and diabetes. Semaglutide, a glucagon-like peptide-1 receptor agonist, improves metabolic h…
Obesity is associated with increased risk of at least 13 adult cancer types and is the second most common cause of cancer (after tobacco) in many populations. Uncertainty about the extent to which intentional weight loss leads to reduced cancer risk…
IMPORTANCE: Heart failure (HF) is a common complication of type 2 diabetes (T2D). Oral semaglutide reduced the risk of major adverse cardiovascular (CV) events (MACE; comprising CV death, nonfatal myocardial infarction, or nonfatal stroke) in people…